Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Letter to the Editor

Tsubasa Tsutsumi, Dan Nakano, Machiko Kawaguchi, Hirokazu Takahashi, Takumi Kawaguchi

Clin Mol Hepatol. 2024;30(2):266-268. Published online January 30, 2024

DOI: https://doi.org/10.3350/cmh.2024.0028

View: 1670 Download: 40 Crossref: 1

Original Article

Prognosis of biopsy-confirmed metabolic dysfunction- associated steatotic liver disease: A sub-analysis of the CLIONE study

Michihiro Iwaki, Hideki Fujii, Hideki Hayashi, Hidenori Toyoda, Satoshi Oeda, Hideyuki Hyogo, Miwa Kawanaka, Asahiro Morishita, Kensuke Munekage, Kazuhito Kawata, Tsubasa Tsutsumi, Koji Sawada, Tatsuji Maeshiro, Hiroshi Tobita, Yuichi Yoshida, Masafumi Naito, Asuka Araki, Shingo Arakaki, Takumi Kawaguchi, Hidenao Noritake, Masafumi Ono, Tsutomu Masaki, Satoshi Yasuda, Eiichi Tomita, Masato Yoneda, Akihiro Tokushige, Yoshihiro Kamada, Hirokazu Takahashi, Shinichiro Ueda, Shinichi Aishima, Yoshio Sumida, Atsushi Nakajima, Takeshi Okanoue

Clin Mol Hepatol. 2024;30(2):225-234. Published online January 24, 2024

DOI: https://doi.org/10.3350/cmh.2023.0515

View: 3116 Download: 186 Crossref: 4

Editorial

Clinical impact of five cardiometabolic risk factors in metabolic dysfunction-associated steatotic liver disease (MASLD): Insights into regional and ethnic differences

Joo Hyun Oh, Dae Won Jun

Clin Mol Hepatol. 2024;30(2):168-170. Published online March 5, 2024

DOI: https://doi.org/10.3350/cmh.2024.0140

View: 1896 Download: 53 Crossref: 1

Letter to the Editor

Changing from NAFLD to MASLD: Similar cumulative incidence of reflux esophagitis between NAFLD and MASLD

Shuhei Fukunaga, Michita Mukasa, Dan Nakano, Tsubasa Tsutsumi, Takumi Kawaguchi

Clin Mol Hepatol. 2024;30(1):121-123. Published online December 4, 2023

DOI: https://doi.org/10.3350/cmh.2023.0437

View: 1559 Download: 73 Web of Science: 4 Crossref: 2

Special Review

Critical appraisal of metabolic dysfunction-associated steatotic liver disease: Implication of Janus-faced modernity

Gi-Ae Kim, Joon Ho Moon, Won Kim

Clin Mol Hepatol. 2023;29(4):831-843. Published online August 25, 2023

DOI: https://doi.org/10.3350/cmh.2023.0277

View: 4009 Download: 352 Web of Science: 12 Crossref: 18

Snapshot

Evaluating the therapeutic efficacy of NAD supplementation in management of metabolic dysfunction-associated steatotic liver disease: Key considerations

Xinyi Lu, Rui Yang, Yu Chen, Daozhen Chen

Received December 21, 2023 Accepted December 28, 2023

DOI: https://doi.org/10.3350/cmh.2023.0555 [Epub ahead of print]

View: 5098 Download: 56

Letter to the Editor

Changing from NAFLD to MASLD: Prevalence and progression of ASCVD risk are similar between NAFLD and MASLD in Asia

Hiroyuki Suzuki, Tsubasa Tsutsumi, Machiko Kawaguchi, Keisuke Amano, Takumi Kawaguchi

Received March 1, 2024 Accepted March 5, 2024

DOI: https://doi.org/10.3350/cmh.2024.0157 [Epub ahead of print]

View: 860 Download: 95 Crossref: 2

Changing from NAFLD to MASLD: Cumulative incidence of gallstones between patients with NAFLD and those with MASLD in Asia

Shuhei Fukunaga, Tomoyuki Nakane, Michita Mukasa, Hidetoshi Takedatsu, Takumi Kawaguchi

Received April 7, 2024 Accepted May 10, 2024

DOI: https://doi.org/10.3350/cmh.2024.0233 [Accepted]

View: 343 Download: 27 Crossref: 1

Equivalent Prevalence and Progression of Chronic Kidney Disease in NAFLD and MASLD

Hiroyuki Suzuki, Tsubasa Tsutsumi, Machiko Kawaguchi, Keisuke Amano, Takumi Kawaguchi

Received April 15, 2024 Accepted May 20, 2024

DOI: https://doi.org/10.3350/cmh.2024.0264 [Accepted]

View: 387 Download: 39

1 |

Viewed By 5351	Prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma under systemic treatment
Viewed By 4958	MAFLD: How is it different from NAFLD?
Viewed By 4656	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 4332	Global incidence and prevalence of nonalcoholic fatty liver disease
Viewed By 3913	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma

Cited By 169	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 108	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 108	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 80	MAFLD: How is it different from NAFLD?
Cited By 77	Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach

Search